Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 149
Filter
1.
Mar Pollut Bull ; 156: 111247, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32510389

ABSTRACT

In six contiguous estuaries in Southwest Florida (USA) focused management actions over the past several decades have reduced watershed nutrient loads, resulting in an additional 11,672 ha of seagrass meadows between 1999 and 2016, an improvement of 32%. However, in September of 2017, Hurricane Irma made landfall in the state of Florida, affecting the open water and watersheds of each of these six estuaries. In response, seagrass coverage declined by 1203 ha between 2016 and 2018, a system-wide decrease of 3%. The range of decreases associated with Hurricane Irma varied from less than a 1% loss of seagrass coverage in St. Joseph Sound to declines of 7 and 11% in Clearwater Harbor and Lemon Bay, respectively. Areas with the largest losses between 2016 and 2018 were those systems where seagrass coverage had declined in prior years, indicating the effects of Hurricane Irma might have been intensified by prior impacts.


Subject(s)
Cyclonic Storms , Estuaries , Florida , Grassland
2.
Mar Pollut Bull ; 135: 1128-1137, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30301011

ABSTRACT

In Southwest Florida, a variety of human impacts had caused widespread losses of seagrass coverage from historical conditions. St. Joseph Sound and Clearwater Harbor lost approximately 24 and 51%, respectively, of their seagrass coverage between 1950 and 1999, while Tampa Bay and Sarasota Bay had lost 46% and 15%, respectively, of their seagrass coverage between 1950 and the 1980s. However, over the period of 1999 to 2016, the largest of the six estuaries, Tampa Bay, added 408 ha of seagrass per year, while the remaining five estuaries examined in this paper added approximately 269 ha per year. In total, seagrass coverage in these six estuaries increased 12,171 ha between the 1980s and 2016. Focused resource management plans have held the line on nitrogen loads from non-point sources, allowing seagrass resources to expand in response to reductions in point source loads that have been implemented over the past few decades.


Subject(s)
Environmental Monitoring/methods , Plants , Aquatic Organisms , Conservation of Water Resources/methods , Ecosystem , Estuaries , Florida , Humans , Nitrogen , Spatio-Temporal Analysis , Water Pollution
3.
Hum Vaccin Immunother ; 12(2): 393-402, 2016.
Article in English | MEDLINE | ID: mdl-26618243

ABSTRACT

Pneumococcal conjugate vaccines (PCVs) have been successful in preventing invasive pneumococcal disease but effectiveness has been challenged by replacement of vaccine serotypes with non-vaccine serotypes. Vaccines targeting common pneumococcal protein(s) found in most/all pneumococci may overcome this limitation. This phase II study assessed safety and immunogenicity of a new protein-based pneumococcal vaccine containing polysaccharide conjugates of 10 pneumococcal serotypes combined with pneumolysin toxoid(dPly) and pneumococcal histidine triad protein D(PhtD) (PHiD-CV/dPly/PhtD-30) in African children. 120 Gambian children (2-4 years, not previously vaccinated against Streptococcus pneumoniae) randomized (1:1) received a single dose of PHiD-CV/dPly/PhtD-30 or PCV13. Adverse events occurring over 4 d post-vaccination were reported, and blood samples obtained pre- and 1-month post-vaccination. Serious adverse events were reported for 6 months post-vaccination. Solicited local and systemic adverse events were reported at similar frequency in each group. One child (PHiD-CV/dPly/PhtD-30 group) reported a grade 3 local reaction to vaccination. Haematological and biochemical parameters seemed similar pre- and 1-month post-vaccination in each group. High pre-vaccination Ply and PhtD antibody concentrations were observed in each group, but only increased in PHiD-CV/dPly/PhtD-30 vaccinees one month post-vaccination. One month post-vaccination, for each vaccine serotype ≥96.2% of PHiD-CV/dPly/PhtD-30 vaccinees had serotype-specific polysaccharide antibody concentrations ≥0.20µg/mL except serotypes 6B (80.8%) and 23F (65.4%), and ≥94.1% had OPA titres of ≥8 except serotypes 1 (51.9%), 5 (38.5%) and 6B (78.0%), within ranges seen in PCV13-vaccinated children. A single dose of PHiD-CV/dPly/PhtD-30 vaccine, administered to Gambian children aged 2-4 y not previously vaccinated with a pneumococcal vaccine, was well-tolerated and immunogenic.


Subject(s)
Antibodies, Bacterial/blood , Hydrolases/immunology , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/adverse effects , Pneumococcal Vaccines/immunology , Streptolysins/immunology , Antibodies, Bacterial/immunology , Bacterial Proteins/immunology , Child, Preschool , Female , Gambia , Humans , Male , Pneumococcal Infections/immunology , Pneumococcal Infections/microbiology , Streptococcus pneumoniae/immunology , Vaccination , Vaccines, Conjugate/immunology
4.
Br J Anaesth ; 114(6): 958-62, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25783742

ABSTRACT

BACKGROUND: Improvements in safety culture have been postulated as one of the mechanisms underlying the association between the introduction of the World Health Organisation (WHO) Surgical Safety Checklist with perioperative briefings and debriefings, and enhanced patient outcomes. The 5 Steps to Safer Surgery (5SSS) incorporates pre-list briefings, the three steps of the WHO Surgical Safety Checklist (SSC) and post-list debriefings in one framework. We aimed to identify any changes in safety culture associated with the introduction of the 5SSS in orthopaedic operating theatres. METHODS: We assessed the safety culture in the elective orthopaedic theatres of a large UK teaching hospital before and after introduction of the 5SSS using a modified version of the Safety Attitude Questionnaire - Operating Room (SAQ-OR). Primary outcome measures were pre-post intervention changes in the six safety culture domains of the SAQ-OR. We also analysed changes in responses to two items regarding perioperative briefings. RESULTS: The SAQ-OR survey response rate was 80% (60/75) at baseline and 74% (53/72) one yr later. There were significant improvements in both the reported frequency (P<0.001) and perceived importance (P=0.018) of briefings, and in five of the six safety culture domain scores (Working Conditions, Perceptions of Management, Job Satisfaction, Safety Climate and Teamwork Climate) of the SAQ-OR (P<0.001 in all cases). Scores in the sixth domain (Stress Recognition) decreased significantly (P=0.028). CONCLUSIONS: Implementation of the 5SSS was associated with a significant improvement in the safety culture of elective orthopaedic operating theatres.


Subject(s)
Organizational Culture , Patient Safety/standards , Perioperative Care/standards , Surgical Procedures, Operative/standards , Attitude of Health Personnel , Checklist , Data Collection , Hospitals, Teaching , Humans , Job Satisfaction , Operating Rooms/standards , Orthopedic Procedures/standards , Patient Care Team/organization & administration , Prospective Studies , Quality Improvement , Stress, Psychological/psychology , Surgical Procedures, Operative/adverse effects
6.
Drugs Today (Barc) ; 47(3): 207-14, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21494698

ABSTRACT

Current pneumococcal conjugate vaccines (PCVs) are highly effective in preventing serotype-specific pneumococcal disease; however, they are relatively expensive and complicated to produce. Furthermore, PCVs do not cover all disease-causing pneumococcal serotypes. While current PCVs are available in industrialized countries and with external assistance in some low-income countries, alternative, more intrinsically affordable pneumococcal vaccines are essential for achieving more widespread use and coverage in resource-limited settings, where vaccines are often inaccessible and need is greatest. This review article describes a number of approaches to develop new PCVs designed to meet this urgent need.


Subject(s)
Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/immunology , Developing Countries , Humans , Vaccines, Conjugate/immunology
7.
Clin Microbiol Infect ; 17 Suppl 3: 1-13, 2011 May.
Article in English | MEDLINE | ID: mdl-21457174

ABSTRACT

In view of the increasing use of pneumococcal vaccines, especially in the developing world, there is a need for appropriate diagnostics to understand the aetiology of pneumonia, to define the burden of pneumococcal disease, and to monitor vaccine efficacy and effectiveness. This article summarizes a meeting on the diagnosis, detection and serotyping of pneumococcal disease organized by PATH and Fondation Mérieux (18-20 October 2009, Fondation Mérieux Conference Centre, Les Pensières, France). Workers and experts met to discuss the gaps in the microbiology-based diagnosis of Streptococcus pneumoniae disease, with special emphasis on pneumonia. The meeting was designed to evaluate the state of the art of pneumococcal diagnostics and serotyping methodologies, identify research and development needs, and propose new guidelines to public health authorities to support the introduction of vaccines. Regarding detection, the main recommendations were to encourage chest X-rays and antigen detection in urine. Large-scale studies are needed to evaluate the diagnostic utility of test algorithms that associate chest X-rays, antigen detection in urine, S. pneumoniae quantitative PCR in nasopharyngeal aspirates and sputum, and C-reactive protein or procalcitonin measurement in blood. Efforts should be focused on proteomics to identify pneumococcus-specific antigens in urine or host markers in blood expressed during pneumonia. It was recommended to develop S. pneumoniae typing capacities, to understand the epidemiology of pneumococcal disease, and to evaluate vaccine effectiveness. Simple and effective approaches are encouraged, and new technologies based on beads, microarrays or deep sequencing should be developed to determine, in a single test capsular serotype, resistance profile and genotype.


Subject(s)
Bacteriological Techniques/methods , Clinical Laboratory Techniques/methods , Pneumonia, Pneumococcal/diagnosis , Streptococcus pneumoniae/isolation & purification , Antigens, Bacterial/urine , France , Genotype , Humans , Microarray Analysis , Molecular Epidemiology , Nasopharynx/microbiology , Pneumonia, Pneumococcal/epidemiology , Pneumonia, Pneumococcal/microbiology , Polymerase Chain Reaction/methods , Radiography, Thoracic , Serotyping , Sputum/microbiology
9.
Infect Immun ; 74(8): 4566-72, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16861643

ABSTRACT

The development of novel vaccine strategies supplementing Mycobacterium bovis BCG (BCG) constitutes an urgent research challenge. To identify potential subunit vaccine candidates, we have tested a series of eight recently identified Mycobacterium tuberculosis antigens in M. bovis-infected and BCG-vaccinated cattle. These antigens were characterized on the basis of their ability to induce in vitro gamma interferon responses in infected or BCG-vaccinated calves. We were able to establish a hierarchy of these antigens based on how frequently they were recognized in both groups of animals. In particular, we were able to prioritize frequently recognized proteins like Rv0287, Rv1174, and Rv1196 for future evaluation as subunit vaccines to be used in BCG-protein heterologous prime-boost vaccination scenarios. In addition, the antigen most dominantly recognized in M. bovis-infected cattle in this study, Rv3616c, was significantly less frequently recognized by BCG vaccinees and could be a target to improve BCG, for example, by increasing its secretion, in a recombinant BCG vaccine.


Subject(s)
Antigens, Bacterial/immunology , BCG Vaccine/administration & dosage , Mycobacterium bovis/immunology , Tuberculosis, Bovine/immunology , Amino Acid Sequence , Animals , Antigens, Bacterial/genetics , BCG Vaccine/immunology , Cattle , Humans , Interferon-gamma/biosynthesis , Leukocytes, Mononuclear/immunology , Molecular Sequence Data , Peptides/chemistry , Peptides/immunology , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Tuberculosis Vaccines , Tuberculosis, Bovine/microbiology , Tuberculosis, Bovine/prevention & control , Vaccination
10.
Tuberculosis (Edinb) ; 83(1-3): 213-9, 2003.
Article in English | MEDLINE | ID: mdl-12758214

ABSTRACT

There have been many new promising approaches to developing human vaccines against tuberculosis (TB). Advances in gene and antigen identification, availability of genome sequences, a greater understanding of immune mechanisms in resistance to TB, the development of adjuvants and delivery systems to stimulate T-cell immunity, and increased funding from public and private agencies are some of the reasons for progress in this area. Dozens of vaccine candidates have been tested in animal models in recent years, and several of these are poised to move into clinical trials in the next several years. Thus, there is renewed optimism for the potential of developing new and improved TB vaccines.


Subject(s)
Tuberculosis Vaccines , Tuberculosis, Pulmonary/prevention & control , Adjuvants, Immunologic , Animals , Antigens, Bacterial/immunology , Disease Models, Animal , Humans , Mycobacterium tuberculosis/immunology
12.
J Immunol ; 166(10): 6227-35, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11342645

ABSTRACT

The development of an effective vaccine against Mycobacterium tuberculosis is a research area of intense interest. Mounting evidence suggests that protective immunity to M. tuberculosis relies on both MHC class II-restricted CD4(+) T cells and MHC class I-restricted CD8(+) T cells. By purifying polypeptides present in the culture filtrate of M. tuberculosis and evaluating these molecules for their ability to stimulate PBMC from purified protein derivative-positive healthy individuals, we previously identified a low-m.w. immunoreactive T cell Ag, Mtb 8.4, which elicited strong Th1 T cell responses in healthy purified protein derivative-positive human PBMC and in mice immunized with recombinant Mtb 8.4. Herein we report that Mtb 8.4-specific T cells can be detected in mice immunized with the current live attenuated vaccine, Mycobacterium bovis-bacillus Calmette-Guérin as well as in mice infected i.v. with M. tuberculosis. More importantly, immunization of mice with either plasmid DNA encoding Mtb 8.4 or Mtb 8.4 recombinant protein formulated with IFA elicited strong CD4(+) T cell and CD8(+) CTL responses and induced protection on challenge with virulent M. tuberculosis. Thus, these results suggest that Mtb 8.4 is a potential candidate for inclusion in a subunit vaccine against TB.


Subject(s)
Antigens, Bacterial/administration & dosage , BCG Vaccine/administration & dosage , Bacterial Proteins , Mycobacterium tuberculosis/immunology , T-Lymphocyte Subsets/immunology , Tuberculosis/prevention & control , Animals , Antibodies, Bacterial/biosynthesis , Antigens, Bacterial/immunology , BCG Vaccine/immunology , Cells, Cultured , Cytotoxicity Tests, Immunologic , DNA, Bacterial/administration & dosage , DNA, Bacterial/immunology , Epitopes, T-Lymphocyte/immunology , Immunoglobulin G/biosynthesis , Injections, Subcutaneous , Interferon-gamma/biosynthesis , Lymphocyte Activation , Macrophages/immunology , Macrophages/microbiology , Mice , Mice, Inbred C57BL , Mycobacterium bovis/immunology , T-Lymphocyte Subsets/microbiology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/microbiology , Th1 Cells/immunology , Th1 Cells/microbiology , Tuberculosis/immunology , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology
13.
J Immunol ; 166(1): 439-46, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11123322

ABSTRACT

Previous studies in murine and human models have suggested an important role for HLA Ia-restricted CD8(+) T cells in host defense to Mycobacterium tuberculosis (Mtb). Therefore, understanding the Ags presented via HLA-Ia will be important in understanding the host response to Mtb and in rational vaccine design. We have used monocyte-derived dendritic cells in a limiting dilution analysis to generate Mtb-specific CD8(+) T cells. Two HLA-Ia-restricted CD8(+) T cell clones derived by this method were selected for detailed analysis. One was HLA-B44 restricted, and the other was HLA-B14 restricted. Both were found to react with Mtb-infected, but not bacillus Calmette-Guérin-infected, targets. For both these clones, the Ag was identified as culture filtrate protein 10 (CFP10)/Mtb11, a 10.8-kDa protein not expressed by bacillus Calmette-Guérin. Both clones were inhibited by the anti-class I Ab and anti-HLA-B,C Abs. Using a panel of CFP10/Mtb11-derived 15-aa peptides overlapping by 11 aa, the region containing the epitopes for both clones has been defined. Minimal 10-aa epitopes were defined for both clones. CD8(+) effector cells specific for these two epitopes are present at high frequency in the circulating pool. Moreover, the CD8(+) T cell response to CFP10/Mtb11 can be largely accounted for by the two epitopes defined herein, suggesting that this is the immunodominant response for this purified protein derivative-positive donor. This study represents the first time CD8(+) T cells generated against Mtb-infected APC have been used to elucidate an Mtb-specific CD8(+) T cell Ag.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/immunology , HLA Antigens/immunology , Histocompatibility Antigens Class I/immunology , Mycobacterium tuberculosis/immunology , Amino Acid Sequence , Antibodies, Blocking/pharmacology , Antibodies, Monoclonal/pharmacology , Antigen Presentation , Antigens, Bacterial/blood , Antigens, Bacterial/immunology , Antigens, Bacterial/metabolism , Bacterial Proteins/blood , Bacterial Proteins/immunology , Bacterial Proteins/metabolism , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/microbiology , Clone Cells , Cytotoxicity Tests, Immunologic , Epitope Mapping , Epitopes, T-Lymphocyte/metabolism , HLA Antigens/metabolism , Histocompatibility Antigens Class I/metabolism , Humans , Jurkat Cells , Lymphocyte Count , Molecular Sequence Data , Tuberculin/blood
14.
J Immunol ; 165(12): 7140-9, 2000 Dec 15.
Article in English | MEDLINE | ID: mdl-11120845

ABSTRACT

Infection of C57BL/6 mice with Mycobacterium tuberculosis results in the development of a progressive disease during the first 2 wk after challenge. Thereafter, the disease is controlled by the emergence of protective T cells. We have used this infection model in conjunction with direct T cell expression cloning to identify Ags involved with the early control of the disease. A protective M. tuberculosis-specific CD4 T cell line derived from mice at 3 wk postchallenge was used to directly screen an M. tuberculosis genomic expression library. This screen resulted in the identification of a genomic clone comprising two putative adjacent genes with predicted open reading frames of 10 and 41 kDa, MTB10 and MTB41, respectively (the products of Rv0916c and Rv0915c, respectively, in the TubercuList H37Rv database). MTB10 and MTB41 belong to the PE and PPE family of proteins recently identified to comprise 10% of the M. tuberculosis genome. Evaluation of the recombinant proteins revealed that MTB41, but not MTB10, is the Ag recognized by the cell line and by M. tuberculosis-sensitized human PBMC. Moreover, C57BL/6 mice immunized with MTB41 DNA developed both CD4- (predominantly Th1) and CD8-specific T cell responses to rMTB41 protein. More importantly, immunization of C57BL/6 mice with MTB41 DNA induced protection against infection with M. tuberculosis comparable to that induced by bacillus Calmette-Guérin. Thus, the use of a proven protective T cell line in conjunction with the T cell expression cloning approach resulted in the identification of a candidate Ag for a subunit vaccine against tuberculosis.


Subject(s)
Antigens, Bacterial/administration & dosage , Antigens, Bacterial/genetics , Antigens, Bacterial/immunology , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/immunology , T-Lymphocytes/metabolism , T-Lymphocytes/microbiology , Tuberculosis/prevention & control , Animals , Antigens, Bacterial/biosynthesis , BCG Vaccine/administration & dosage , BCG Vaccine/genetics , BCG Vaccine/immunology , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/immunology , Cell Culture Techniques , Cell Line , Cells, Cultured , Cloning, Molecular/methods , Epitopes, T-Lymphocyte/immunology , Gene Expression Regulation, Bacterial/immunology , Genomic Library , Humans , Injections, Intramuscular , Mice , Mice, Inbred C57BL , Spleen/cytology , Spleen/immunology , Tuberculosis/genetics , Tuberculosis/immunology , Vaccines, DNA/administration & dosage , Vaccines, DNA/immunology
15.
J Clin Microbiol ; 38(9): 3285-90, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10970372

ABSTRACT

In order to identify antigens that may be used in the serodiagnosis of active tuberculosis (TB), we screened a Mycobacterium tuberculosis genomic expression library with a pool of sera from patients diagnosed with active pulmonary TB. The sera used lacked reactivity with a recombinant form of the M. tuberculosis 38-kDa antigen (r38kDa), and the goal was to identify antigens that might complement r38kDa in a serodiagnostic assay. Utilizing this strategy, we identified a gene, previously designated lhp, which encodes a 100-amino-acid protein referred to as culture filtrate protein 10 (CFP-10). The lhp gene is located directly upstream of esat-6, within a region missing in M. bovis BCG. Immunoblot analysis demonstrated that CFP-10 is present in M. tuberculosis CFP, indicating that it is likely a secreted or shed antigen. Purified recombinant CFP-10 (rCFP-10) was shown to be capable of detecting specific antibody in a percentage of TB patients that lack reactivity with r38kDa, most notably in smear-negative cases, where sensitivity was increased from 21% for r38kDa alone to 40% with the inclusion of rCFP-10. In smear-positive patient sera, sensitivity was increased from 49% for r38kDa alone to 58% with the inclusion of rCFP-10. In addition, rCFP-10 was shown to be a potent T-cell antigen, eliciting proliferative responses and gamma interferon production from peripheral blood mononuclear cells in 70% of purified protein derivative-positive individuals without evident disease. The responses to this antigen argue for the inclusion of rCFP-10 in a polyvalent serodiagnostic test for detection of active TB infection. rCFP-10 could also contribute to the development of a recombinant T-cell diagnostic test capable of detecting exposure to M. tuberculosis.


Subject(s)
Antigens, Bacterial/immunology , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Mycobacterium tuberculosis/immunology , Tuberculosis, Pulmonary/diagnosis , Adolescent , Adult , Amino Acid Sequence , Antibodies, Bacterial/blood , Antigens, Bacterial/chemistry , Antigens, Bacterial/genetics , Bacterial Proteins/chemistry , Bacterial Proteins/isolation & purification , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoblotting , Lymphocyte Activation , Male , Molecular Sequence Data , Mycobacterium bovis/genetics , Mycobacterium bovis/immunology , Mycobacterium tuberculosis/genetics , Recombinant Proteins/chemistry , Recombinant Proteins/immunology , Tuberculosis, Pulmonary/microbiology
16.
J Immunol ; 165(2): 925-30, 2000 Jul 15.
Article in English | MEDLINE | ID: mdl-10878367

ABSTRACT

Previous studies in mice and humans models have suggested an important role for CD8+ T cells in host defense to Mycobacterium tuberculosis (Mtb). In humans, CD8+ Mtb-reactive T cells have been described that are HLA-A2-, B52-, as well as CD1-restricted. Recently, we have described Mtb-specific CD8+ T cells that are neither HLA-A-, B-, or C- nor group 1 CD1-restricted. At present, little is known about the relative contribution of each of these restriction specificities to the overall CD8+ response to Mtb. An IFN-gamma enzyme-linked immunospot assay was used to determine the frequency of Mtb-reactive CD8+ T cells directly from PBMC. The effector cell frequency among five healthy purified protein derivative-positive subjects was 1/7,600 +/- 4,300 compared with 1/16,000 +/- 7,000 in six purified protein derivative-negative controls. To determine the frequencies of classically, CD1-, and nonclassically restricted cells, a limiting dilution analysis was performed. In one purified protein derivative-positive subject, 192 clones were generated using Mtb-infected dendritic cells (DC). Clones were assessed for reactivity against control autologous DC, Mtb-infected autologous DC, and HLA-mismatched CD1+ targets (DC), as well as HLA-mismatched CD1- targets (macrophages). Of the 96 Mtb-reactive CD8+ T cell clones, four (4%) were classically restricted and 92 (96%) were nonclassically restricted. CD1-restricted cells were not detected. Of the classically restricted cells, two were HLA-B44 restricted and one was HLA-B14 restricted. These results suggest that while classically restricted CD8+ lymphocytes can be detected, they comprise a relatively small component of the overall CD8+ T cell response to Mtb. Further definition of the nonclassical response may aid development of an effective vaccine against tuberculosis.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/microbiology , HLA Antigens/immunology , Mycobacterium tuberculosis/immunology , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/metabolism , Antigen-Presenting Cells/microbiology , Antigens, CD1/immunology , CD8-Positive T-Lymphocytes/metabolism , Clone Cells , Dendritic Cells/immunology , Dendritic Cells/metabolism , Dendritic Cells/microbiology , Enzyme-Linked Immunosorbent Assay , Humans , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Leukocytes, Mononuclear/microbiology , Lymphocyte Activation/immunology , Lymphocyte Count , Macrophages/immunology , Macrophages/metabolism , Macrophages/microbiology , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocyte Subsets/microbiology , T-Lymphocytes, Regulatory/immunology , T-Lymphocytes, Regulatory/metabolism , T-Lymphocytes, Regulatory/microbiology , Tuberculin/immunology , Tuberculosis/immunology
17.
J Exp Med ; 191(3): 551-60, 2000 Feb 07.
Article in English | MEDLINE | ID: mdl-10662800

ABSTRACT

Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) is likely to be dependent on the identification of T cell antigens that induce strong proliferation and interferon gamma production from healthy purified protein derivative (PPD)(+) donors. We have developed a sensitive and rapid technique for screening an Mtb genomic library expressed in Escherichia coli using Mtb-specific CD4(+) T cells. Using this technique, we identified a family of highly related Mtb antigens. The gene of one family member encodes a 9.9-kD antigen, termed Mtb9.9A. Recombinant Mtb9.9A protein, expressed and purified from E. coli, elicited strong T cell proliferation and IFN-gamma production by peripheral blood mononuclear cells from PPD(+) but not PPD(-) individuals. Southern blot analysis and examination of the Mtb genome sequence revealed a family of highly related genes. A T cell line from a PPD(+) donor that failed to react with recombinant Mtb9.9A recognized one of the other family members, Mtb9.9C. Synthetic peptides were used to map the T cell epitope recognized by this line, and revealed a single amino acid substitution in this region when compared with Mtb9.9A. The direct identification of antigens using T cells from immune donors will undoubtedly be critical for the development of vaccines to several intracellular pathogens.


Subject(s)
Antigens, Bacterial/genetics , CD4-Positive T-Lymphocytes/metabolism , Mycobacterium tuberculosis/immunology , Amino Acid Sequence , Antigens, Bacterial/chemistry , Antigens, Bacterial/immunology , Bacterial Vaccines , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/microbiology , Cell Line , Cloning, Molecular , Escherichia coli/genetics , Escherichia coli/metabolism , Genes, Bacterial , Genomic Library , Humans , Molecular Sequence Data
18.
Clin Rheumatol ; 18(4): 283-92, 1999.
Article in English | MEDLINE | ID: mdl-10468167

ABSTRACT

The 'Program for Rheumatic Independent Self-Management' (PRISM) is an interdisciplinary programme that integrates group education and individualised treatment using the principles of self-management, adult learning, case management and self-efficacy enhancement. This study is a before-after evaluation of 57 individuals who attended PRISM. Outcome measures were selected to measure self-efficacy, disability, pain and ability to cope. The mean self-efficacy score increased immediately following the programme and this improvement was maintained at 6-month follow-up. Disability decreased from baseline to 6-month follow-up. There was a decrease in the mean level of pain from post-class to 6-month follow-up. All of these changes were statistically significant. These preliminary findings suggest that PRISM may be effective in enhancing self-efficacy, and reducing disability and pain.


Subject(s)
Arthritis, Rheumatoid/rehabilitation , Self Care , Self Efficacy , Adolescent , Adult , Aged , Arthralgia/etiology , Arthralgia/rehabilitation , Arthritis, Rheumatoid/complications , Disability Evaluation , Female , Humans , Male , Middle Aged , Patient Education as Topic , Pilot Projects , Retrospective Studies , Rural Population , Self Care/methods , Self Care/standards , Severity of Illness Index , Surveys and Questionnaires , Treatment Outcome
19.
Infect Immun ; 67(8): 3998-4007, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10417166

ABSTRACT

Culture filtrate proteins (CFP) of Mycobacterium tuberculosis have been shown to contain immunogenic components that elicit at least partial protective immunity against Mycobacterium infection. To clone genes encoding some of the immunogenic proteins, we made a high-titer rabbit anti-CFP serum and used it to screen an M. tuberculosis genomic expression library in Escherichia coli. In this paper, we describe the molecular cloning of two new protein components of CFP and identified them as members of the serine protease gene family. Their open reading frames contain N-terminal hydrophobic secretory signals consistent with their detection in CFP. The predicted molecular masses of the mature, fully processed forms of both antigens are approximately 32 kDa, in agreement with their observed sizes on immunoblots of CFP probed with polyclonal rabbit antisera made to the recombinant proteins. Thus, these proteins have been designated MTB32A and MTB32B. Interestingly, and despite 66% amino acid sequence homology between the two proteins, polyclonal rabbit antisera made to each of the recombinant proteins were found to be specific for the respective immunizing antigens. The recombinant proteins were also evaluated in in vitro assays with donor peripheral blood mononuclear cells (PBMC) from healthy purified protein derivative (PPD)-positive individuals of diverse ethnic backgrounds. MTB32A but not MTB32B stimulated PBMC from healthy PPD-positive donors but not from PPD-negative donors to proliferate and secrete gamma interferon. MTB32A is encoded by a single-copy gene which is present in both virulent and avirulent strains of the M. tuberculosis complex and the BCG strain of Mycobacterium bovis but absent in the environmental mycobacterial species tested. In addition, nucleotide sequence comparison of mtb32a of the avirulent H37Ra strain and the virulent Erdman strain, as well as with the corresponding sequences (identified in the databases) of strain H37Rv and the clinical isolate CSU93, revealed 100% identity. MTB32A, therefore, represents a candidate for inclusion in subunit vaccine development. Finally, the possible role of MTB32 serine proteases as a virulence factor(s) during Mycobacterium spp. infection is discussed.


Subject(s)
Antigens, Bacterial/immunology , Bacterial Proteins/immunology , Mycobacterium tuberculosis/immunology , Serine Endopeptidases/immunology , Amino Acid Sequence , Animals , Antigens, Bacterial/chemistry , Bacterial Proteins/chemistry , Bacterial Proteins/genetics , Base Sequence , Blotting, Western , Cloning, Molecular , Conserved Sequence , Humans , Interferon-gamma/biosynthesis , Lymphocyte Activation , Molecular Sequence Data , Rabbits , Serine Endopeptidases/chemistry , Serine Endopeptidases/genetics
20.
Infect Immun ; 67(6): 2941-50, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10338503

ABSTRACT

We have used expression screening of a genomic Mycobacterium tuberculosis library with tuberculosis (TB) patient sera to identify novel genes that may be used diagnostically or in the development of a TB vaccine. Using this strategy, we have cloned a novel gene, termed mtb39a, that encodes a 39-kDa protein. Molecular characterization revealed that mtb39a is a member of a family of three highly related genes that are conserved among strains of M. tuberculosis and Mycobacterium bovis BCG but not in other mycobacterial species tested. Immunoblot analysis demonstrated the presence of Mtb39A in M. tuberculosis lysate but not in culture filtrate proteins (CFP), indicating that it is not a secreted antigen. This conclusion is strengthened by the observation that a human T-cell clone specific for purified recombinant Mtb39A protein recognized autologous dendritic cells infected with TB or pulsed with purified protein derivative (PPD) but did not respond to M. tuberculosis CFP. Purified recombinant Mtb39A elicited strong T-cell proliferative and gamma interferon responses in peripheral blood mononuclear cells from 9 of 12 PPD-positive individuals tested, and overlapping peptides were used to identify a minimum of 10 distinct T-cell epitopes. Additionally, mice immunized with mtb39a DNA have shown increased protection from M. tuberculosis challenge, as indicated by a reduction of bacterial load. The human T-cell responses and initial animal studies provide support for further evaluation of this antigen as a possible component of a subunit vaccine for M.tuberculosis.


Subject(s)
Antigens, Bacterial/genetics , Genes, Bacterial , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/immunology , T-Lymphocytes/immunology , Tuberculosis/immunology , Adolescent , Amino Acid Sequence , Animals , Antigens, Bacterial/immunology , BCG Vaccine/immunology , Dendritic Cells/immunology , Female , Humans , Leukocytes, Mononuclear/immunology , Male , Mice , Mice, Inbred C57BL , Middle Aged , Molecular Sequence Data , Multigene Family , Rabbits , Tuberculosis/blood , Tuberculosis/microbiology , Tuberculosis/prevention & control , Vaccination , Vaccines, DNA/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...